for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Beyond Air Inc

XAIR.OQ

Latest Trade

11.61USD

Change

-0.42(-3.49%)

Volume

266,445

Today's Range

11.29

 - 

12.20

52 Week Range

4.63

 - 

12.60

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
12.03
Open
12.10
Volume
266,445
3M AVG Volume
12.33
Today's High
12.20
Today's Low
11.29
52 Week High
12.60
52 Week Low
4.63
Shares Out (MIL)
23.95
Market Cap (MIL)
288.09
Forward P/E
-9.91
Dividend (Yield %)
--

Next Event

Q2 2022 Beyond Air Inc Earnings Release

Latest Developments

More

Beyond Air Posts Q1 Loss Per Share Of $0.31

Beyond Air Reports Financial Results For Fourth Fiscal Quarter And Year-End 2021

Beyond Air® Reports Financial Results For Third Quarter Of Fiscal Year 2021 And Provides Business Update

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Beyond Air Inc

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company. The Company is engaged in developing a nitric oxide (NO) generator and delivery system through its LungFit platmorfm that is capable of generating NO from ambient air. Its pipeline includes LungFit PH designed to deliver a dosage of NO to the lungs for the treatment of Persistent Pulmonary Hypertension of the Newborn (PPHN), LungFit PRO for the treatment of viral lung infections for adults, which is commonly caused by rhinovirus, respiratory syncytial virus (RSV) and influenza virus and LungFit GO for the treatment of rare and serious pulmonary disease associated with increased morbidity and mortality called Nontuberculous mycobacteria (NTM) lung infection.

Industry

Medical Equipment & Supplies

Contact Info

825 E Gate Blvd Ste 320

GARDEN CITY, NY

11530-2135

United States

+1.516.6658200

http://www.ait-pharm.com

Executive Leadership

Steven A. Lisi

Chairman of the Board, Chief Executive Officer

Amir Avniel

President, Chief Operating Officer, Director

Douglas Larson

Chief Financial Officer

Duncan Fatkin

Chief Commercial Officer

Peter Dzedora Senior

Director of Business Development

Key Stats

1.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020

0.0K

2021

0.0K

2022(E)

0.0K
EPS (USD)

2019

-1.260

2020

-1.780

2021

-1.270

2022(E)

-1.182
Price To Earnings (TTM)
--
Price To Sales (TTM)
447.33
Price To Book (MRQ)
8.37
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
14.51
LT Debt To Equity (MRQ)
13.47
Return on Investment (TTM)
-73.07
Return on Equity (TTM)
-64.40

Latest News

Latest News

BRIEF-Beyond Air Reports Q4 Loss Per Share $0.36

* BEYOND AIR REPORTS FINANCIAL RESULTS FOR FISCAL FOURTH QUARTER AND YEAR-END 2020

BRIEF-Beyond Air Receives Approval From Health Canada To Study Nitric Oxide Generated And Delivered By The Lungfit™ In Covid-19 Patients

* BEYOND AIR RECEIVES APPROVAL FROM HEALTH CANADA TO STUDY NITRIC OXIDE GENERATED AND DELIVERED BY THE LUNGFIT™ IN COVID-19 PATIENTS

BRIEF-Beyond Air Enters Into New Common Stock Purchase Agreement

* BEYOND AIR ENTERS INTO NEW COMMON STOCK PURCHASE AGREEMENT EXTENDING RELATIONSHIP WITH LINCOLN PARK CAPITAL

BRIEF-Beyond Air Says U.S. FDA Agreed With Initiation Of Clinical Study In U.S. Using Its Lungfit System To Treat Covid-19 Patients

* BEYOND AIR - U.S. FOOD AND DRUG ADMINISTRATION AGREED WITH INITIATION OF CLINICAL STUDY IN U.S. USING ITS LUNGFIT SYSTEM TO TREAT COVID-19 PATIENTS Source text for Eikon: Further company coverage:

BRIEF-Beyond Air Enters Into Sales Agreement With Suntrust, Oppenheimer Related To Stock Offered

* BEYOND AIR INC - ENTERED INTO SALES AGREEMENT WITH SUNTRUST, OPPENHEIMER RELATING TO SHARES OF COMMON STOCK OFFERED BY PROSPECTUS SUPPLEMENT

BRIEF-Beyond Air Submits Investigational Device Exemption To The United States FDA For The Treatment Of COVID-19 Patients

* BEYOND AIR SUBMITS INVESTIGATIONAL DEVICE EXEMPTION (IDE) TO THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) FOR THE TREATMENT OF COVID-19 PATIENTS

BRIEF-Charles Mosseri Marlio Reports 9.8% Passive Stake In Beyond Air

* CHARLES MOSSERI MARLIO REPORTS 9.8% PASSIVE STAKE IN BEYOND AIR INC AS OF MARCH 9, 2020 - SEC FILING Source: (http://bit.ly/3cTbArz) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up